Key Highlights

  • Chrysos Corporation (ASX:C79) reported FY26 Revenue of $88.1 million, compared with $66.1 million in FY25, an increase of 33%.
  • EBITDA reached $27.2 million, compared with $16.1 million in FY25, while EBITDA Margin increased from 24% to 31%.
  • PhotonAssay sample volumes reached 11.3 million for FY26, up 67%, with more than one million samples processed per month for five consecutive months.
  • The company ended FY26 with $25.9 million in cash and $140 million of undrawn Debt , while FY27 guidance calls for revenue of $108 million to $118 million and EBITDA of $35 million to $42 million.

Chrysos Corporation (ASX:C79) reported its FY26 results for the year ended 30 June 2026, with revenue of $88.1 million, compared with $66.1 million in FY25. The company said the result was at the upper end of its previously stated guidance and was accompanied by increased deployment and utilisation of its PhotonAssay technology.

The company recorded EBITDA of $27.2 million, up from $16.1 million in the previous financial year. EBITDA margin was 31%, compared with 24% in FY25.

During FY26, Chrysos signed 24 new PhotonAssay Lease agreements. Four additional agreements were signed after the reporting period, taking total contracted units to 87. At 30 June 2026, 46 units had been deployed, compared with 40 units a year earlier, while the number of lease agreements increased to 83 from 59.

Seven units were deployed during FY26 across Canada, Australia and Chile, while six additional units were in the process of deployment at the reporting date.

PhotonAssay Volumes Reach Record Level

Sample processing volumes increased to 11.3 million during FY26, representing a 67% increase from FY25. Chrysos reported more than one million samples processed in each month for five consecutive months from March 2026.

Monthly processing subsequently exceeded 1.1 million samples in July 2026.

The increase in sample volumes was reflected in the composition of revenue. Minimum Monthly Assay Payments reached $62.5 million, compared with $55.9 million in FY25, representing a 12% increase.

Additional Assay Charges increased to $25.5 million from $10.1 million, an increase of 153%. These charges accounted for 29% of total FY26 revenue, compared with 15% in FY25.

Expansion Across Laboratories and Mining Operations

Chrysos reported deployments involving major laboratory groups during the year. The company now has PhotonAssay units deployed with all four major laboratories.

Seven units were deployed during FY26, including three with ALS. A unit was also deployed for MSA at its Grand Falls-Windsor laboratory in Canada, while another was deployed to Intertek's laboratory in Norseman, Western Australia.

The first next-generation XN unit was deployed to SGS in Perth.

The company also reported direct-to-mine lease agreements involving Newmont, Acrux Gold, Alkane Resources, Pantoro and Allied Gold. Agreements included a second unit at Newmont's Merian mine in Suriname, Acrux Gold's Cononish Project in Scotland, Alkane's Bjorkdal mine in Sweden, Pantoro's Norseman mine in Australia, and Allied Gold's Sadiola and Kurmuk operations.

Cash Generation and Funding Capacity

Chrysos recorded net operating cash inflows of $17.9 million in FY26, compared with $8.8 million in FY25, representing an increase of 103%.

At 30 June 2026, the company held $25.9 million in cash and had $140 million in undrawn debt facilities. During the year, Chrysos completed a new three-year $200 million syndicated debt Facility provided by ANZ, National Australia Bank and Export Finance Australia.

The new facility replaced the previous asset-based financing structure and added $105 million in funding headroom. The company said the facility also included changes to debt pricing, commitment fees and covenant terms.

FY27 Guidance

For FY27, Chrysos has provided revenue guidance of $108 million to $118 million and EBITDA guidance of $35 million to $42 million.

The company is targeting a Manufacturing cadence of 18 units per year. Its contracted fleet stood at 87 units following the four post-period lease agreements, while six units were deploying at the end of FY26.

The FY27 guidance is based on constant-currency assumptions, including AUD/USD of 0.6945, AUD/CAD of 0.9627, AUD/GBP of 0.522, AUD/EUR of 0.6018 and AUD/NZD of 1.1923.

Conclusion

Chrysos Corporation's FY26 results included revenue of $88.1 million, EBITDA of $27.2 million, 11.3 million PhotonAssay samples processed and 83 contracted units at year-end. The company entered FY27 with 87 contracted units following post-period agreements, $25.9 million of cash and $140 million of undrawn debt facilities. Management's FY27 guidance is for revenue of $108 million to $118 million and EBITDA of $35 million to $42 million.